Exelixis
EXEL · NASDAQ
Bulios Fair Price
$69.14
17.5% upside
Trenutna cena
$58.85
Po podatkih Bulios Fair Price je delnica EXEL trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Exelixis, Inc. is an American biotechnology company focused on the development and commercialization of innovative therapies in the field of oncology. The company concentrates on the research and development of new therapeutic options for the treatment of various types of cancer, including liver, lung, and kidney cancer. Exelixis is known for its main drug, cabozantinib, which is used to treat several cancer types. The company collaborates with other biotechnology and pharmaceutical firms to develop new drugs and therapies.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Morrissey
Employees
1,077
Headquarters
Alameda
Prihajajoči dogodki
Earnings
Upcoming earnings report